Cell penetrating peptides functionalized gambogic acid-nanostructured lipid carrier for cancer treatment

References

• Attama AA. (2011). SLN, NLC, LDC: state of the art in drug and active delivery. Recent Pat Drug Deliv Formul 5:178–87.
   PubMedGoogle Scholar
• Chabner B, Roberts T. (2005). Timeline: chemotherapy and the war on cancer. Nat Rev Cancer 5:65–72.
   PubMed Web of Science ®Google Scholar
• Chaudhary B, Khaled YS, Ammori BJ, et al. (2014). Neuropilin 1: function and therapeutic potential in cancer. Cancer Immunol Immunother 63:81–99.
   PubMed Web of Science ®Google Scholar
• Chen G, Wang L, Cordie T, et al. (2015). Multi-functional self-fluorescent unimolecular micelles for tumor-targeted drug delivery and bioimaging. Biomaterials 47:41–50.
   PubMed Web of Science ®Google Scholar
• Chi Y, Zhan XK, Yu H, et al. (2013). An open-labeled, randomized, multicenter phase IIa study of gambogic acid injection for advanced malignant tumors. Chin Med J 126:1642–6.
   PubMed Web of Science ®Google Scholar
• Dubey PK, Singodia D, Verma RK, et al. (2011). RGD modified albumin nanospheres for tumour vasculature targeting. J Pharm Pharmacol 63:33–40.
   PubMed Web of Science ®Google Scholar
• Fang G, Tang B, Chao Y, et al. (2015). Improved oral bioavailability of docetaxel by nanostructured lipid carriers: in vitro characteristics, in vivo evaluation and intestinal transport studies. RSC Adv 5:96437–47.
   Web of Science ®Google Scholar
• Graf N, Bielenberg DR, Kolishetti N. (2012). α(V)β(3) Integrin-targeted PLGA-PEG nanoparticles for enhanced anti-tumor efficacy of a Pt(IV) prodrug. ACS Nano 6:4530–9.
   PubMed Web of Science ®Google Scholar
• Gu H, Rao S, Zhao J, et al. (2009). Gambogic acid reduced bcl-2 expression via p53 in human breast MCF-7 cancer cells. J Cancer Res Clin Oncol 135:1777–82.
   PubMed Web of Science ®Google Scholar
• Gu H, Wang X, Rao S, et al. (2008). Gambogic acid mediates apoptosis as a p53 inducer through down-regulation of mdm2 in wild-type p53-expressing cancer cells. Mol Cancer Ther 32:3298–3305.
   Web of Science ®Google Scholar
• Guo Y, Niu B, Song Q, et al. (2016). RGD-decorated redox-responsive d-α-tocopherol polyethylene glycol succinate-poly (lactide)nanoparticles for targeted drug delivery. J Mater Chem B 4:2338–50.
   PubMed Web of Science ®Google Scholar
• Hao K, Liu XQ, Wang GJ, et al. (2007). Pharmacokinetics, tissue distribution and excretion of gambogic acid in rats. Eur J Drug Metab Pharmacokinet 32:63–8.
   PubMed Web of Science ®Google Scholar
• Hynes RO. (2002). A reevaluation of integrins as regulators of angiogenesis. Nat Med 8:918–21.
   PubMed Web of Science ®Google Scholar
• Jin H, Varner J. (2004). Integrins: roles in cancer development and as treatment targets. Br J Cancer 90:561–5.
   PubMed Web of Science ®Google Scholar
• Liu YT, Hao K, Liu X, et al. (2006). Metabolism and metabolic inhibition of gambogic acid in rat liver microsomes. Acta Pharmacol Sin 27:1253–8.
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhao H, Shu L, et al. (2015). Preparation and evaluation of Baicalin-loaded cationic solid lipid nanoparticles conjugated with OX26 for improved delivery across the BBB. Drug Dev Industr Pharm 41:353–61.
   PubMed Web of Science ®Google Scholar
• Miura Y, Takenaka T, Toh K, et al. (2013). Cyclic RGD-linked polymeric micelles for targeted delivery of platinum anticancer drugs to glioblastoma through the blood-brain tumor barrier. ACS Nano 7:8583–92.
   PubMed Web of Science ®Google Scholar
• Padhye SG, Nagarsenker MS. (2013). Simvastatin solid lipid nanoparticles for oral delivery: formulation development and in vivo evaluation. Indian J Pharm Sci 75:591–8.
   PubMed Web of Science ®Google Scholar
• Pandey MK, Sung B, Ahn KS, et al. (2007). Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-kappaB signaling pathway. Blood 110:3517–25.
   PubMed Web of Science ®Google Scholar
• Pérez-Herrero E, Fernández-Medarde A. (2015). Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm 93:52–79.
   PubMed Web of Science ®Google Scholar
• Poonia N, Kharb R, Lather V, et al. (2016). Nanostructured lipid carriers: versatile oral delivery vehicle. Future Sci OA 2:FSO135.
   PubMed Web of Science ®Google Scholar
• Prud’homme G, Glinka Y. (2012). Neuropilins are multifunctional coreceptors involved in tumor initiation, growth, metastasis and immunity. Oncotarget 3:921–39.
   PubMed Web of Science ®Google Scholar
• Qi Q, Lu N, Wang X, et al. (2008). Anti-invasive effect of gambogic acid in MDA-MB-231 human breast carcinoma cells. Biochem Cell Biol 86:386–95.
   PubMed Web of Science ®Google Scholar
• Selvamuthukumar S, Velmurugan R. (2011). Nanostructured lipid carriers: a potential drug carrier for cancer chemotherapy. Lipids Health Dis 11:159.
   Web of Science ®Google Scholar
• Setyawati MI, Tay CY, Docter D, et al. (2015). Understanding and exploiting nanoparticles’ intimacy with the blood vessel and blood. Chem Soc Rev 44:8174–99.
   PubMed Web of Science ®Google Scholar
• Sharma P, Brown S, Walter G, et al. (2006). Nanoparticles for bioimaging. Adv Colloid Interface Sci 123–126:471–85.
   PubMed Web of Science ®Google Scholar
• Shi KL, Cao J, Yang ZP, et al. (2015). A pH-responsive cell-penetrating peptide-modified liposomes with active recognizing of integrin αvβ3 for the treatment of melanoma. J Control Release 27:38–150.
   Google Scholar
• Steichen SD, Caldorera-Moore M, Peppas NA. (2013). A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci 48:416–27.
   PubMed Web of Science ®Google Scholar
• Uner M. (2006). Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC): their benefits as colloidal drug carrier systems. Int J Pharm Sci 61:375–86.
   Google Scholar
• Wang X, Chen WT. (2012). Gambogic acid is a novel anti-cancer agent that inhibits cell proliferation, angiogenesis and metastasis. Anticancer Agents Med Chem 12:994–1000.
   PubMed Web of Science ®Google Scholar
• Wang CL, Zhang HJ, Chen Y, et al. (2012). Gambogic acid-loaded magnetic Fe(3)O(4) nanoparticles inhibit Panc-1 pancreatic cancer cell proliferation and migration by inactivating transcription factor ETS1. Int J Nanomed 7:781–7.
   PubMed Web of Science ®Google Scholar
• Williams HD, Trevaskis NL, Yeap YY. (2013). Lipid-based formulations and drug supersaturation: harnessing the unique benefits of the lipid digestion/absorption pathway. Pharm Res 30:2976–92.
   PubMed Web of Science ®Google Scholar
• Yang Y, Yang L, You QD, et al. (2007). Differential apoptotic induction of gambogic acid, a novel anticancer natural product, on hepatoma cells and normal hepatocytes. Cancer Lett 256:259–66.
   PubMed Web of Science ®Google Scholar
• Yu F, He C, Waddad AY, et al. (2013). N-Octyl-N-arginine-chitosan (OACS) micelles for gambogic acid oral delivery: preparation, characterization and its study on in situ intestinal perfusion. Drug Dev Ind Pharm 40:774–82.
   PubMed Web of Science ®Google Scholar
• Zhang HZ, Kasibhatla S, Wang Y, et al. (2004). Discovery, characterization and SAR of gambogic acid as a potent apoptosis inducer by a HTS assay. Bioorg Med Chem 12:309–17.
   PubMed Web of Science ®Google Scholar
• Zhang ZH, Wang XP, Ayman WY, et al. (2013). Studies on lactoferrin nanoparticles of gambogic acid for oral delivery. Drug Deliv 20:86–93.
   PubMed Web of Science ®Google Scholar
• Zhong Y, Meng F, Deng C, et al. (2014). Ligand-directed active tumor-targeting polymeric nanoparticles for cancer chemotherapy. Biomacromolecules 15:1955–69.
   PubMed Web of Science ®Google Scholar
• Zhu X, Zhang C, Wu XL, et al. (2008). Preparation, physical properties, and stability of gambogic acid loaded micelles based on chitosan derivatives. Drug Dev Ind Pharm 34:2–9.
   PubMed Web of Science ®Google Scholar